The early-stage biotech company, focused on developing therapies for rare diseases, has announced an asset purchase agreement with Codexis, Inc. for the acquisition of Codexis' investigational engineered enzymes that target Fabry and Pompe diseases. CAMBRIDGE, Mass., July 10, 2024...
↧